BRAF and melanoma: Samples were analyzed using the Sequenom MassARRAY MelaCarta panel of recurrently mutated melanoma genes, and also by direct Sanger sequencing of BRAF exon 15, which served to identify the full extent of BRAF exon 15 mutations, and to provide validation of the BRAF MelaCarta mutation data.